Interaction between HER2 and ATM predicts poor survival in bladder cancer patients

Nada Albarakati1,2 | Alaa Al-Shareeda2,3,4 | Majed Ramadan2,5 | Batla Al-Sowayan2,3 | Ola Negm6,7 | Taoufik Nedjadi1,2

Abstract

Human Epidermal Growth Factor Receptor 2 (HER2) overexpression is considered one of the interesting prognostic biomarkers in bladder cancer. However, the mechanism of bladder cancer development in relation to HER2 status remains to be elucidated. In this study, we investigated HER2-Ataxia telangiectasia mutated (ATM) kinase interaction and their impact on patient survival and cancer aggressiveness. Using the Cancer Genome Atlas (TCGA) cohorts, we demonstrated that ATM expression (protein/mRNA) is increased in HER2 deficient compared with proficient HER2 patients. This finding was then validated using the Gene Expression Omnibus database (GEO). Correlation analysis (using low expression vs high expression as a discriminator) revealed a significant association of ATM low and HER2 high status with several clinicopathological variables such as high tumour grade, late disease stage and tumour shape. Kaplan–Meier survival analysis indicated that ATM low and HER2 high is a powerful prognosticator of both overall survival (OS) and disease-free survival (DFS). Furthermore, using bioinformatics and protein/protein interaction analyses, we identified 66 putative overlapping proteins with direct link between HER2 and ATM most of which are functionally involved in transcription regulation, apoptotic process and cell proliferation. Interestingly, the results showed that these proteins are strongly linked with PI3K-Akt pathway, p53 pathway and microRNAs in cancer. Altogether, our data pinpoint an important biological role of the interconnection between HER2 and ATM. The latter appear to be an independent prognostic biomarker and may serve as targets to develop novel combination therapies to improve the outcome of patients with bladder cancer.

KEYWORDS

ATM, Bladder cancer, HER2, Prognosis
1 | INTRODUCTION

Bladder cancer is the 10th most diagnosed type of cancer globally. In men, it is the 4th most common cancer and the 8th leading cause of cancer death.\(^1\)\(^,\)\(^2\) Based on the latest Globocan data, approximately 580,000 new cases and 220,000 deaths due to bladder cancer occurred in 2020 and are expected to double in the upcoming years.\(^2\) Urothelial bladder carcinoma is the most common type of the disease as it originates mainly from the inner layer of the bladder (urothelium). Approximately 75% of urothelial cancer cases are classified as non-muscle invasive bladder cancer (NMIBC) with the remaining 25% being muscle invasive bladder cancer (MIBC) which is likely to metastasize to lymph nodes or other organs.\(^3\) Despite advances in cancer diagnosis and therapy, bladder cancer remains a source of challenge to clinicians and healthcare providers due to high recurrence rates and the aggressive phenotype.\(^4\) Hence, prognostic biomarkers are desperately needed to predict outcome and optimize the treatment protocol for bladder cancer patients. Recent advances in sequencing and genomics have yielded a wealth of information that could be used in personalized medicine and targeted cancer therapy. For instance, Human Epidermal Growth Factor Receptor 2 (HER2), Fibroblast Growth Factor Receptor (FGFR), Mammalian target of rapamycin (mTOR) and immune checkpoint inhibitors; currently used in clinical practice.\(^5\)\(^-\)\(^10\) Several studies provide evidence on the prognosis benefit of HER2 amplification or overexpression levels in bladder cancer, suggesting the potential benefits of HER2 targeted therapies on patients’ survival.\(^11\)\(^-\)\(^14\)

HER2 is a transmembrane glycoprotein receptor tyrosine kinase of the EGFR (growth factor receptor family). Increased activity of HER2 has been evaluated and was associated with poor prognostic in breast, gastric and bladder cancers.\(^15\) Recently, 2411 bladder tumours were sequenced and six distinct molecular subtypes were identified; HER2-like is one of them.\(^16\),\(^17\) Today, HER2 is considered one of the important prognostic biomarkers in bladder cancer.\(^18\),\(^19\)

Early data revealed that HER2-targeted therapy is beneficial for metastatic or advanced carcinoma patients with HER2 overexpression.\(^20\),\(^21\) However, a phase II trial for patients with advanced or metastatic urothelial cancer overexpressing HER2 treated with trastuzumab combined with chemotherapy showed similar results achieved with chemo alone.\(^22\),\(^23\) A more recent study indicated that patients with recurrent urothelial bladder cancer and amplified HER2 gene benefited from trastuzumab and chemotherapy.\(^23\) The aforementioned studies highlight the clinical relevance of HER2 and the utility of anti-HER2 targeted therapy as an alternative treatment in bladder cancer. However, the exact molecular mechanisms underlying the effect of HER2, including the crosstalk between HER2 and other signalling pathways such as Ataxia telangiectasia mutated (ATM) kinase, remain to be elucidated.\(^24\) ATM is a tumour suppressor gene that works as a genomic stability guardian due to its essential role in DNA damage response and repair.\(^25\) In bladder cancer, ATM/RB1 mutations predicted poorer survival.\(^26\),\(^27\) In breast cancer, ATM activity reduced recurrence time in patients with invasive HER2-positive; moreover ATM was found to be involved in HER2 tumour progression.\(^28\),\(^29\) In gastric cancer, ATM low protein expression subtype was exclusive with HER2 high protein expression.\(^30\)

The aim of the current study was to describe an integrative analysis of HER2 and ATM interaction using the Cancer Genome Atlas (TCGA) bladder cancer cohorts to highlight the importance of both genes as potential prognosticators for bladder cancer patients. We sought to determine the expression of HER2 and ATM at the protein and mRNA levels in bladder cancer cohorts to understand their relationship and investigate their impact on patient survival and cancer aggressiveness. Also, we attempted to identify the overlapping proteins between HER2 and ATM pathways to provide a deeper insight into the molecular interactions and functional mechanisms between these two biomarkers.

2 | MATERIALS AND METHODS

2.1 | Study cohorts

The current study is a retrospective study using four cohorts. Cohort one; ERBB2 and ATM mRNA expression in a panel of different cancer types (bladder, breast, colon, kidney renal clear cell, kidney renal papillary cell, kidney chromophobe, uterine corpus endometrial, thyroid, liver and stomach) extracted from TCGA datasets along with normal match. Excluding cancer types with less than 19 samples and cancer types with no significant different between the mRNA levels in tumours and the respective normal tissues. Data were examined in UALCAN a publicly available interactive online portal (http://ualcan.path.uab.edu/index.html).\(^31\) Cohort two; TCGA MIBC dataset (n = 413) was used to evaluate HER2 and ATM mRNA, protein expressions and clinicopathological information provided by cbioPortal.\(^32\),\(^33\) In this cohort, mRNA expression z-scores (RNA Seq V2 RSEM) measured by Agilent microarray and protein expression z-scores measured by Reverse Phase Protein Array (RPPA). All data extracted from cbioPortal (https://www.cbioportal.org/) originally from Bladder Cancer (TCGA, Cell 2017)\(^34\) and can be found in Table S1. We defined mRNA and protein under- or over-expression if the value is greater/less than the median cut-point of HER2 factor. Cohort three; From the Gene Expression Omnibus (GEO) database (https://www.ncbi.nlm.nih.gov/geo/), the GSE13507 (Platform GPL6102) dataset was obtained.\(^35\),\(^36\) In this cohort, 10 normal bladder mucosae samples, 58 normal looking bladder mucosae surrounding cancer and 165 primary bladder cancer samples were profiled for ERBB2 and ATM mRNA expression using Illumina human-6 v2.0 expression beadchip. Cohort four; GSE32548 (Platform GPL6947) also from GEO database. This cohort is 131 primary bladder cancer tumour samples analysed with Illumina HumanHT-12 V3.0 expression beadchip.\(^37\)

2.2 | Data processing, Protein–Protein Interaction (PPI) network construction and co-expressed proteins identification

In order to obtain a PPI network between HER2 and ATM, we first used Reactome (https://reactome.org/) a pathway database,\(^38\) to find
all related pathways/functions where both of our protein targets are involved. The median score of each target from Cohort two RPPA data was used. To find both functional and physical networks between our targets, we proceed with STRING (version 11.0), multiple proteins database, which will evaluate the interactive relationships (https://string-db.org/). Using experiments, co-expression and co-occurrence as active interaction sources at high confidence (0.700). All nodes with direct interaction with both HER2 and ATM were obtained, then all co-expressed proteins were visualized by Cytoscape (https://cytoscape.org/). To analyse the network, NetworkAnalyzer, a plugin in Cytoscape, was applied to calculate the topology parameters. Then a centrality calculation was performed by Cytohubba, a plugin in Cytoscape, using degree as a topological method in order to explore the important nodes in our sub-network.

2.3 Functional and pathway enrichment analysis

The Database for Annotation, Visualization and Integrated Discovery tool (DAVID; version 6.8: https://david.ncifcrf.gov/home.jsp) was used to provide Gene Ontology analysis including biological process, molecular function, cellular component and also Kyoto Encyclopedia of Gene and Genomes pathway analysis (KEGG). Pathway enrichment analysis was performed with the threshold of $p < 0.05$.

2.4 Statistical analyses

Data analysis was performed using JMP Pro 15 (SAS Institute Inc., USA). In the univariate analysis, Chi-square test ($\chi^2$) for more than five subjects per cell and Fisher exact test for less than five subjects per cell were used to evaluate the relationship between HER2 and ATM factors expression and clinicopathological variables. For the prognostic significance survival curves, Kaplan–Meier analysis was used with log-rank comparison test. In multivariate analysis, to emphasize on HER2-ATM interaction, Cox proportional hazard model was used for the multivariate survival analysis including all potential confounder factors. The proportional hazards assumption was checked, the relationship between log cumulative hazard and a covariate was linear. Where appropriate, two-tailed Student's t-test was performed using GraphPad Prism (version 8.4.3, USA). All differences were considered statistically significant at $p < 0.05$, $p$ values were two-sided; all confidence intervals were at 95%.

3 RESULTS

3.1 Analysis of HER2 and ATM expression levels in human cancers

We initially profiled the expression pattern of ERBB2 and ATM mRNA levels in a panel of different normal and tumour tissues with bioinformatics analyses using the TCGA database (Cohort one). The data revealed an inverse relationship between the mRNA levels in tumours and the respective normal tissues in all organs. Interestingly, we noticed that when the ERBB2 level is high in cancer compared with the matching normal tissue, the ATM level in cancer shows deregulation compared with ATM levels in normal matched tissue. This is more obvious in bladder, breast, uterine corpus endometrial and thyroid. However, when the ERBB2 expression in cancer is impaired compared with the matching normal tissue, the ATM level increases compared with the matching normal tissue, as illustrated in colon, kidney renal clear cell and kidney renal papillary cell cancers. ERBB2 and ATM levels both increases in liver cancer, stomach cancer and both decreases in kidney chromophobe cancer (Figure 1A). It is also important to emphasize that the thresholds of ERBB2 expression are higher than the thresholds of ATM expression in all tissues.

3.2 Relationship between HER2 and ATM in bladder cancer

We investigated the balancing mechanism between HER2 and ATM at protein and mRNA levels using bladder cancer TCGA cohort from the cBioPortal database. The current bladder cancer TCGA cohort (Cohort two) included 413 patients diagnosed with MIBC. The mean age at diagnosis was 68 years, ranging from 34 to 90 years old with a median age of 69; the median follow-up time is 17.61 months (ranging from 0 to 165.9 months). The distribution of the clinicopathological characteristics of the patients is presented in Table 1. In this cohort, first, we found that HER2 protein expression, measured by RPPA, was significantly higher than ATM protein expression as expected; $p = 0.0002$ (Figure 1B). Interestingly, when we sub grouped ATM-positive and ATM-negative patients according to HER2 status, we found that ATM expression levels increased significantly in HER2 deficient patients compared with proficient HER2 patients ($p = 0.008$).

Similarly, at mRNA levels (Figure 1C), total ERBB2 was significantly higher than ATM levels ($p < 0.0001$), and high ATM expression was observed when ERBB2 was low compared with high ERBB2 ($p = 0.0009$). This data was validated in an independent cohort using GEO GSE13507 dataset accessible from the National Center for Biotechnology Information (NCBI), in this cohort (Cohort three), 10 normal bladder mucosae samples, 58 normal looking bladder mucosae surrounding cancer and 165 primary bladder cancer samples were profiled for ERBB2 and ATM mRNA expression using Illumina human-6 v2.0 expression beadchip. Figure 1D, shows total ERBB2 expression (mean = 7.8) significantly low than ATM (mean = 9) in both normal sets ($p < 0.0001$). However, in primary cancer samples, ERBB2 mean increase to 8.1 with a decrease of ATM to 8.4 ($p < 0.0001$). Interestingly, the ATM levels increased significantly in ERBB2 deficient patients compared with ERBB2 proficient patients ($p < 0.0001$). We validated this finding with second dataset from GEO (Cohort four) GSE32548 (Platform GPL6947). This cohort consist of 131 primary bladder
cancer tumour samples analysed with Illumina HumanHT-12 V3.0 expression beadchip. As expected (Figure 1E), total ERBB2 was significantly higher than ATM levels \((p < 0.0001)\) and ATM levels increased significantly in ERBB2− compared to ERBB2+ patients \((p = 0.0187)\).

3.3 | Relationships between ATM, HER2 factors and clinical outcome

Considering the inverse relationship between the HER2 level and the ATM level, we sought to investigate whether HER2 and ATM expression factors affects patient prognosis. To do so, first we looked at the TCGA cohort (Cohort two) and observed a significant impact of combining high ERBB2/HER2 expression on the overall survival (OS); \(p = 0.024\) and disease-free survival (DFS); with borderline significance \((p = 0.068)\) (Figure S1A,B). Whereas the ATM/ATM expression levels had no prognostic value (Figure S1C,D). Though neither HER2 nor ATM factors alone show any significance on the OS or DFS at the protein level (Figure S2A–D) or the mRNA levels in this cohort. However, the ERBB2 showed a significant poor DFS for patients with amplified ERBB2; \(p = 0.032\) (Figure S3A–D). Based on Kaplan–Meier, patients with low ATM protein level and low ATM mRNA showed a tendency toward poor OS \((p = 0.057)\), and poor DFS \((p = 0.078)\) (Figure S2C,D).

Then, we stratified patients into two subgroups according to the HER2 status. Our data indicated that patients with low ATM and high HER2 expression strongly predicts poor OS and DFS; \(p = 0.008\) and \(p = 0.018\), respectively (Figure 2A,B). In contrast, ATM levels did not show any difference on patients’ survival when HER2 was low (Figure 2C,D). Also, no significance was seen for ATM mRNA levels with different ERBB2 status (Figure S4A–D). The combination of low HER2 and high ATM expression was significantly associated with late disease stage \((p = 0.026)\), no association was observed with any other clinicopathological variables (Table S2).

3.4 | HER2-ATM Co-expression in bladder cancer

Interestingly, when stratified the whole population based on both HER2/ATM protein expression status, patients with low ATM/high

**FIGURE 1** (A) Boxplot of the mRNA expression levels of ERBB2 and ATM in different cancer types, along with matching normal tissue \((N = \text{normal} \text{ and } T = \text{tumour})\). (B) Dot plot showing the protein expression levels of HER2 and ATM in bladder cancer patients, and ATM expression under different HER2 levels. (C) TCGA Dot plot showing the mRNA expression levels of ERBB2 and ATM in bladder cancer patients, and ATM expression under different ERBB2 levels. (D) GEO-GSE13507 Dot plot showing the mRNA expression levels of ERBB2 and ATM in bladder cancer patients, along with normal samples and ATM expression under different ERBB2 levels. (E) GEO-GSE32548 Dot plot showing the mRNA expression levels of ERBB2 and ATM in bladder cancer patients, and ATM expression under different ERBB2 levels. *\(p < 0.05\), **\(p < 0.01\), ***\(p < 0.001\) and ****\(p < 0.0001\). All data were analysed by the two-tailed Student’s t-test.
## Table 1: Association of HER2, ERBB2 expressions and clinicopathological variables in TCGA dataset

| Group age (Years) | Whole cohort | ERBB2 non-amplified | ERBB2 amplified | p value |
|-------------------|--------------|---------------------|----------------|---------|
| >60               | 392 (94.92%) | 191 (46.25%)        | 197 (47.70%)   | 0.347   |
| ≤60               | 20 (4.84%)   | 12 (2.91%)          | 8 (1.94%)      |         |
| Unknown           | 1 (0.24%)    | 1 (0.24%)           | 0 (0.00%)      |         |

| Gender | Whole cohort | ERBB2 non-amplified | ERBB2 amplified | p value |
|--------|--------------|---------------------|----------------|---------|
| Male   | 304 (73.61%) | 144 (34.87%)        | 157 (38.01%)   | 0.195   |
| Female | 108 (26.15%) | 59 (14.29%)         | 48 (11.62%)    |         |
| Unknown| 1 (0.24%)    | 1 (0.24%)           | 0 (0.00%)      |         |

| Tumour grade | Whole cohort | ERBB2 non-amplified | ERBB2 amplified | p value |
|--------------|--------------|---------------------|----------------|---------|
| Low Grade    | 21 (5.08%)   | 199 (48.18%)        | 185 (44.79%)   | 0.003   |
| High Grade   | 388 (93.95%) | 4 (0.97%)           | 17 (4.12%)     |         |
| Unknown      | 4 (0.97%)    | 1 (0.24%)           | 3 (0.73%)      |         |

| Tumour stage | Whole cohort | ERBB2 non-amplified | ERBB2 amplified | p value |
|--------------|--------------|---------------------|----------------|---------|
| T3b          | 82 (19.85%)  | 47 (11.38%)         | 34 (8.23%)     | 0.161   |
| T3a          | 71 (17.19%)  | 34 (8.23%)          | 37 (8.96%)     |         |
| T2b          | 56 (13.56%)  | 32 (7.75%)          | 24 (5.81%)     |         |
| T4a          | 43 (10.41%)  | 19 (4.60%)          | 24 (5.81%)     |         |
| T3           | 42 (10.17%)  | 21 (5.08%)          | 21 (5.08%)     |         |
| T2           | 38 (9.20%)   | 14 (3.39%)          | 24 (5.81%)     |         |
| Unknown      | 33 (7.99%)   | 18 (4.36%)          | 15 (3.63%)     |         |
| T2a          | 27 (6.54%)   | 7 (1.69%)           | 18 (4.36%)     |         |
| T4           | 11 (2.66%)   | 7 (1.69%)           | 3 (0.73%)      |         |
| T4b          | 5 (1.21%)    | 2 (0.48%)           | 3 (0.73%)      |         |
| T1           | 3 (0.73%)    | 2 (0.48%)           | 1 (0.24%)      |         |
| T0           | 1 (0.24%)    | 1 (0.24%)           | 0 (0.00%)      |         |
| TX           | 1 (0.24%)    | 0 (0.00%)           | 1 (0.24%)      |         |

| Disease stage | Whole cohort | ERBB2 non-amplified | ERBB2 amplified | p value |
|---------------|--------------|---------------------|----------------|---------|
| Stage III     | 141 (34.14%) | 85 (20.58%)         | 55 (13.32%)    | 0.015   |
| Stage IV      | 136 (32.93%) | 57 (13.80%)         | 77 (18.64%)    |         |
| Stage II      | 131 (31.72%) | 59 (14.29%)         | 71 (17.19%)    |         |
| Unknown       | 3 (0.73%)    | 2 (0.48%)           | 1 (0.24%)      |         |
| Stage I       | 2 (0.48%)    | 1 (0.24%)           | 1 (0.24%)      |         |

(Continues)
|                                | Whole cohort | Whole cohort | Whole cohort |
|--------------------------------|--------------|--------------|--------------|
|                                | N   | %          | N   | %          | N   | %          | p value |
| **ERBB2 non-amplified**        |     |            |     |            |     |            |         |
|                                |     |            |     |            |     |            |         |
| **ERBB2 amplified**            |     |            |     |            |     |            |         |
|                                |     |            |     |            |     |            |         |
| **HER2 Low expression**        |     |            |     |            |     |            |         |
|                                |     |            |     |            |     |            |         |
| **HER2 High expression**       |     |            |     |            |     |            |         |
|                                |     |            |     |            |     |            |         |
| **Tumour shape**               |     |            |     |            |     |            |         |
| Non-papillary                  | 274 | 66.34%     | 151 | 36.56%     | 119 | 28.81%     | <0.001  |
| Papillary                      | 133 | 32.20%     | 48  | 11.62%     | 85  | 20.58%     |         |
| Unknown                        | 6   | 1.45%      | 5   | 1.21%      | 1   | 0.24%      |         |
| **Lymph node**                 |     |            |     |            |     |            |         |
| YES                            | 296 | 71.67%     | 149 | 36.08%     | 143 | 34.62%     | 0.144   |
| NO                             | 79  | 19.13%     | 33  | 7.99%      | 46  | 11.14%     |         |
| Unknown                        | 38  | 9.20%      | 22  | 5.33%      | 16  | 3.87%      |         |
| **Lymph node stage**           |     |            |     |            |     |            |         |
| N0                             | 239 | 57.87%     | 133 | 32.20%     | 104 | 25.18%     | 0.021   |
| N2                             | 76  | 18.40%     | 27  | 6.54%      | 48  | 11.62%     |         |
| N1                             | 47  | 11.38%     | 21  | 5.08%      | 25  | 6.05%      |         |
| NX                             | 36  | 8.72%      | 14  | 3.39%      | 22  | 5.33%      |         |
| N3                             | 8   | 1.94%      | 4   | 0.97%      | 4   | 0.97%      |         |
| Unknown                        | 7   | 1.69%      | 5   | 1.21%      | 2   | 0.48%      |         |
| **Metastasis**                 |     |            |     |            |     |            |         |
| YES                            | 213 | 51.57%     | 114 | 27.60%     | 96  | 23.24%     | 0.052   |
| NO                             | 196 | 47.46%     | 87  | 21.07%     | 100 | 25.15%     |         |
| Unknown                        | 4   | 0.97%      | 3   | 0.73%      | 1   | 0.24%      |         |
| **Metastasis stage**           |     |            |     |            |     |            |         |
| MX                             | 202 | 48.91%     | 108 | 26.15%     | 91  | 22.03%     | 0.151   |
| M0                             | 196 | 47.46%     | 87  | 21.07%     | 108 | 26.15%     |         |
| M1                             | 11  | 2.66%      | 6   | 1.45%      | 5   | 1.21%      |         |
| Unknown                        | 4   | 0.97%      | 3   | 0.73%      | 1   | 0.24%      |         |
| **Family history of cancer**   |     |            |     |            |     |            |         |
| NO                             | 262 | 63.44%     | 119 | 28.81%     | 142 | 34.38%     | 0.020   |
| YES                            | 147 | 35.59%     | 83  | 20.10%     | 61  | 14.77%     |         |
| Unknown                        | 4   | 0.97%      | 2   | 0.48%      | 2   | 0.48%      |         |
| **Smoking**                    |     |            |     |            |     |            |         |
| YES                            | 259 | 62.71%     | 134 | 32.45%     | 123 | 29.78%     | 0.234   |
| NO                             | 154 | 37.29%     | 70  | 16.95%     | 82  | 19.85%     |         |

**Note:** N number of cases; significant values (p < 0.05) are highlighted in bold.
HER2 appear to have significant poor outcome compared with the other three subgroups (ATM low/HER2 low, ATM high/HER2 high and ATM high/HER2 low) in OS ($p = 0.025$) and DFS ($p = 0.024$) (Figure S5A,B). Similarly, at the mRNA level, patients with low ATM and amplified ERBB2 showed a significant poor DFS ($p = 0.046$) but not OS (Figure S5C,D).

### 3.5 | Relationship between ATM/HER2 and clinicopathological features

To evaluate the relationship of ATM/HER2 status and the clinicopathological parameters, we used univariate analysis. Our data indicate that mRNA expression of ATM/ERBB2 was significantly associated with tumour grade ($p = 0.011$), disease stage ($p = 0.009$) and tumour shape ($p = 0.001$). Similarly, it was identified in the ATM/HER2 protein level with tumour grade ($p < 0.001$), disease stage ($p = 0.008$), tumour shape ($p < 0.001$), in addition to lymph node ($p = 0.046$) and metastasis ($p = 0.001$) (Table 2). Multivariate analysis was conducted to investigate whether HER2/ATM expression is an independent prognostic factor. As shown in Table 3, multivariate analyses including other validated prognostic factors (such as tumour grade, lymph node, tumour shape, metastasis stage) and ATM expression (OS; $p = 0.003$, Hazard ratio = 0.343, 95% CI = 0.171–0.689, DFS; $p = 0.003$, Hazard ratio = 0.298, 95% CI = 0.134–0.667) independently predicted poor clinical outcome. HER2/ATM co-expression was an independent prognostic of worse survivals (OS; $p = 0.038$, Hazard ratio = 2.739, 95% CI = 1.063–7.057, DFS; $p = 0.041$, Hazard ratio = 1.477; 95% CI = 1.017–2.133). Interestingly, HER2+/ATM expression group was in independent prognostic of worse survival (OS; $p = 0.012$, Hazard ratio = 0.593, 95% CI = 0.394–0.892, DFS; $p = 0.001$, Hazard ratio = 0.125; 95% CI = 0.036–0.607) but not HER2−/ATM group.
|                        | ATM/ERBB2 (Gene level) | ATM/HER2 (Protein level) | p value | ATM/HER2 (Protein level) | p value |
|------------------------|------------------------|--------------------------|---------|--------------------------|---------|
|                        | N (%)                  | N (%)                    |         | N (%)                    | N (%)   |
| Group age (Years)      |                        |                          |         |                          |         |
| Unknown                | 0 0.00%                | 0 0.00%                  | 0.00%   | 0 0.00%                  | 0.00%   |
| ≤60                    | 7 1.69%                | 6 1.45%                  | 0.48%   | 2 1.21%                  | 2 0.48% |
| >60                    | 93 22.52%              | 98 23.73%                | 99 23.97%| 98 23.73%                | 0.398   |
| Gender                 |                        |                          |         |                          |         |
| Unknown                | 0 0.00%                | 0 0.00%                  | 0.00%   | 0 0.00%                  | 0.00%   |
| Male                   | 73 17.68%              | 81 19.61%                | 76 18.40%| 71 17.19%                | 0.512   |
| Female                 | 27 6.54%               | 23 5.57%                 | 25 6.05%| 32 7.75%                 |         |
| Tumour grade           |                        |                          |         |                          |         |
| Unknown                | 0 0.00%                | 1 0.24%                  | 1 0.24% | 0 0.00%                  | 0.000   |
| Low grade              | 1 0.24%                | 11 2.66%                 | 6 1.45% | 3 0.73%                  |         |
| High grade             | 99 23.97%              | 92 22.28%                | 93 22.52%| 100 24.21%               | 0.011   |
| Disease stage          |                        |                          |         |                          |         |
| Unknown                | 1 0.24%                | 0 0.00%                  | 1 0.24% | 1 0.24%                  | 0.009   |
| Stage I                | 0 0.00%                | 0 0.00%                  | 0 0.00% | 1 0.24%                  | 0.008   |
| Stage II               | 36 8.72%               | 39 9.44%                 | 32 7.75%| 23 5.57%                 |         |
| Stage III              | 37 8.96%               | 33 7.99%                 | 22 5.33%| 48 11.62%                |         |
| Stage IV               | 26 6.30%               | 32 7.75%                 | 45 10.90%| 31 7.51%                 |         |
| Tumour shape           |                        |                          |         |                          |         |
| Unknown                | 2 0.48%                | 0 0.00%                  | 1 0.24% | 3 0.73%                  | 0.001   |
| Non-Papillary          | 77 18.64%              | 55 13.32%                | 64 15.50%| 74 17.92%                |         |
| Papillary              | 21 5.08%               | 49 11.86%                | 36 8.72%| 27 6.54%                 |         |
| Lymph node             |                        |                          |         |                          |         |
| Unknown                | 10 2.42%               | 4 0.97%                  | 12 2.91%| 12 2.91%                 | 0.331   |
| NO                     | 19 4.60%               | 26 6.30%                 | 20 4.84%| 14 3.39%                 | 0.046   |
| YES                    | 71 17.19%              | 74 17.92%                | 69 16.71%| 78 18.89%                |         |
| Metastasis             |                        |                          |         |                          |         |
| Unknown                | 0 0.00%                | 0 0.00%                  | 1 0.24% | 3 0.73%                  | 0.001   |
| NO                     | 40 9.69%               | 53 12.83%                | 55 13.32%| 47 11.38%                |         |
| YES                    | 60 14.53%              | 51 12.35%                | 45 10.90%| 54 13.08%                |         |

Note: N number of cases; significant values (p < 0.05) are highlighted in bold.
### TABLE 3  Multivariate analysis for predictors of overall and disease-free survival

| Factors          | Overall survival | Disease-free survival |
|------------------|------------------|-----------------------|
|                  | Hazard ratio     | 95% confidence interval | p value | Hazard ratio | 95% confidence interval | p value |
|                  | Lower bound      | Upper bound            |         | Lower bound  | Upper bound            |         |
| Gender           | 0.806            | 0.558                  | 1.164   | 0.243        | 0.681                  | 0.432   | 1.043   | 0.078 |
| Tumour grade     | 0.431            | 0.218                  | 0.851   | 0.019        | 0.387                  | 0.182   | 0.823   | 0.014 |
| Tumour Stage     | 0.713            | 0.356                  | 1.431   | 0.341        | 0.862                  | 0.652   | 1.133   | 0.288 |
| Lymph Node       | 0.468            | 0.293                  | 0.748   | 0.002        | 0.470                  | 0.257   | 0.886   | 0.020 |
| Tumour Shape     | 1.866            | 1.326                  | 2.627   | <0.0001      | 2.594                  | 1.671   | 4.032   | <0.0001 |
| Metastasis Stage | 1.249            | 0.882                  | 1.769   | 0.209        | 1.635                  | 1.077   | 2.509   | 0.021 |
| ATM expression   | 0.343            | 0.171                  | 0.689   | 0.003        | 0.298                  | 0.134   | 0.667   | 0.003 |
| HER2 expression  | 0.970            | 0.689                  | 1.367   | 0.864        | 0.832                  | 0.550   | 1.259   | 0.385 |
| HER2/ATM expression | 2.739        | 1.063                  | 7.057   | 0.038        | 1.477                  | 1.017   | 2.133   | 0.041 |
| HER2+/ATM expression | 0.593        | 0.394                  | 0.892   | 0.012        | 0.125                  | 0.036   | 0.607   | 0.001 |
| HER2−/ATM expression | 0.938        | 0.609                  | 1.434   | 0.768        | 1.276                  | 0.794   | 2.050   | 0.311 |

Abbreviations: ATM, Ataxia telangiectasia mutated; HER2, Human Epidermal growth factor Receptor 2; HER2/ATM, co-expression. Hazard ratio, 95% Confidence Interval and p value are shown. Significant results are highlighted in bold.

**FIGURE 3** (A) Venn diagram of common pathways between HER2 and ATM. (B) Protein–protein interaction network demonstrating all overlapping proteins. (C) Protein–protein interaction of 66 proteins with direct link to both HER2 and ATM.
3.6 Identification of overlapping proteins between HER2 and ATM

In order to understand how the ATM/HER2 status can affect the prognosis for bladder cancer patients, we investigated the overlapping PPI between the HER2 and ATM pathways using Reactome pathway database tool. By using the median score of both proteins from the TCGA Cohort two, we were able to identify 217 pathways for HER2 and 140 pathways for ATM. Three pathways only show both proteins; Generic Transcription Pathway, RNA Polymerase II Transcription and Gene expression (Transcription); Figure 3A. Next, we analysed PPI between HER2, ATM and all proteins in the three pathways by submitting all data to STRING (PPI Networks); Figure 3B. Our network with high confidence and experiments, co-expression and co-occurrence as active interaction sources; shows a total of 1311 nodes and 5028 edges. Among all these nodes a total of 66 overlapping proteins were directly linked between HER2 and ATM (Figure 3C) visualized manually by Cytoscape software. In addition, Networkanalyzer and Cythubba analysis of the sub-network shows 68 nodes and 1426 edges. Table 4 is a PPI ranked by degree method illustrating the degree, betweenness centrality and closeness centrality. Also, 11 topological analysis methods were applied (Table S3). Then, we assessed the significant differentness in the overlapping proteins in the stratified patients cohort (Cohort two) according to HER2-ATM status. Data identified that in the low HER2 cohort and different ATM levels (high/low); ABL1, SMAD4, RB1 and PARP1 were significantly upregulated and AKT1, AKT2, TSC2, RPTOR and mTOR were significantly downregulated in bladder cancer (Table S4).

3.7 Functional and pathway enrichment analyses

Next, we sought to analyse the functional enrichment pathways of the ATM/HER2 using the TCGA-Bladder cancer cohort. A list of overlapping proteins was uploaded to DAVID software to identify significant GO categories and KEGG pathways. The results demonstrated that HER2/ATM overlapping proteins were markedly enriched in Molecular Function, including protein binding, DNA binding, protein kinase binding, enzyme binding and ATP binding (Figure 4A). GO Biological Process analysis showed enrichment of positive regulation of transcription from RNA polymerase II promoter, positive regulation of transcription, DNA-templated, positive regulation of apoptotic process and negative regulation of cell proliferation (Figure 4B). Also, GO Cellular component analysis revealed that the overlapping proteins are significantly enriched in several sub-cellular compartments including the nucleus, nucleoplasm, cytosol, cytoplasm and mitochondrion (Figure 4C). As for the results of KEGG pathway analysis, the data indicated that the overlapping proteins are mainly enriched in pathways in cancer, PI3K-Akt signalling pathway, microRNAs in cancer, cell cycle and p53 signalling pathway (Figure 4D); fully functional and pathway enrichment analyses are shown in Figure 5.
| Rank | Name  | Uniprot ID | Degree | Betweenness centrality | Closeness centrality | Rank | Name  | Uniprot ID | Degree | Betweenness centrality | Closeness centrality |
|------|-------|------------|--------|------------------------|---------------------|------|-------|------------|--------|------------------------|---------------------|
| 1    | TP53  | Q8J016     | 67     | 0.0233                 | 1.0000              | 35   | SKP2  | Q13309     | 40     | 0.0030                 | 0.7128              |
| 1    | ATM   | Q13315     | 67     | 0.0233                 | 1.0000              | 35   | CHEK2 | Q9UGF1     | 40     | 0.0034                 | 0.7128              |
| 3    | MYC   | P01106     | 66     | 0.0223                 | 0.9853              | 35   | INS   | P01308     | 40     | 0.0025                 | 0.7128              |
| 4    | PTEN  | P60484     | 65     | 0.0181                 | 0.9710              | 38   | H2AFX | P16104     | 39     | 0.0044                 | 0.7053              |
| 5    | ERBB2 | P04626     | 64     | 0.0210                 | 0.9571              | 39   | CREB1 | P16220     | 37     | 0.0019                 | 0.6907              |
| 6    | CTNNB1| P35222     | 63     | 0.0151                 | 0.9437              | 40   | PGR   | P06401     | 36     | 0.0012                 | 0.6837              |
| 6    | CDKN2A| P42771     | 63     | 0.0162                 | 0.9437              | 40   | E2F1  | Q01094     | 36     | 0.0017                 | 0.6837              |
| 8    | EGFR  | Q9H2C9     | 62     | 0.0165                 | 0.9306              | 42   | RPS27A| Q9UPK7     | 35     | 0.0017                 | 0.6768              |
| 9    | Kras  | P01116     | 60     | 0.0131                 | 0.9054              | 42   | BCL2L11| Q8WYM1     | 35     | 0.0007                 | 0.6768              |
| 9    | AKT1  | P31749     | 60     | 0.0142                 | 0.9054              | 42   | IL6   | P05231     | 35     | 0.0006                 | 0.6768              |
| 11   | BRCA1 | P38398     | 58     | 0.0135                 | 0.8816              | 42   | CCNE2 | Q96020     | 35     | 0.0022                 | 0.6768              |
| 12   | MDM2  | Q53XW0     | 57     | 0.0103                 | 0.8701              | 46   | RAD51 | E9PI54     | 34     | 0.0033                 | 0.6700              |
| 12   | ESR1  | P03372     | 57     | 0.0099                 | 0.8701              | 46   | AKT2  | P31751     | 34     | 0.0018                 | 0.6700              |
| 14   | JUN   | P05412     | 55     | 0.0101                 | 0.8481              | 48   | AURKB | Q96GD4     | 33     | 0.0020                 | 0.6634              |
| 15   | CDK4  | P11802     | 54     | 0.0091                 | 0.8375              | 48   | UBC   | Q9UPK7     | 33     | 0.0015                 | 0.6634              |
| 15   | NOTCH1| P46531     | 54     | 0.0090                 | 0.8375              | 50   | CYCS  | P99999     | 32     | 0.0006                 | 0.6569              |
| 17   | CCNA2 | P20248     | 53     | 0.0079                 | 0.8272              | 51   | NPM1  | Q96DC4     | 31     | 0.0009                 | 0.6505              |
| 17   | CCNK1A| P38936     | 53     | 0.0065                 | 0.8272              | 51   | UBB   | Q9UPK7     | 31     | 0.0011                 | 0.6505              |
| 19   | CCNB1 | P14635     | 52     | 0.0082                 | 0.8171              | 53   | TSC2  | Q8TAZ1     | 30     | 0.0012                 | 0.6442              |
| 20   | SMAD4 | Q13485     | 51     | 0.0092                 | 0.8072              | 53   | ARID1A| Q9HB5      | 30     | 0.0012                 | 0.6442              |
| 21   | EZH2  | Q15910     | 50     | 0.0069                 | 0.7976              | 53   | BMW1  | P35226     | 30     | 0.0007                 | 0.6442              |
| 21   | MTOR  | P42345     | 50     | 0.0064                 | 0.7976              | 53   | UBA52 | Q9UPK7     | 30     | 0.0011                 | 0.6442              |
| 21   | PARP1 | P09874     | 50     | 0.0061                 | 0.7976              | 53   | MLH1  | P40692     | 29     | 0.0012                 | 0.6381              |
| 24   | CDKN1B| P46527     | 49     | 0.0050                 | 0.7882              | 58   | MSH2  | P43246     | 28     | 0.0013                 | 0.6321              |
| 25   | HDAC1 | Q13547     | 48     | 0.0051                 | 0.7791              | 58   | CDKN2B| P42771     | 28     | 0.0005                 | 0.6321              |
| 26   | RB1   | P06400     | 47     | 0.0047                 | 0.7701              | 60   | SMARCB1| Q12824     | 27     | 0.0007                 | 0.6262              |
| 27   | FOXL3 | O43524     | 46     | 0.0046                 | 0.7614              | 60   | HDAC6 | Q9UBN7     | 27     | 0.0014                 | 0.6262              |
| 28   | CCNE1 | P24864     | 45     | 0.0047                 | 0.7528              | 62   | YAP1  | P46937     | 25     | 0.0012                 | 0.6147              |
| 29   | MAPK3 | P27361     | 44     | 0.0043                 | 0.7444              | 63   | KMT2C | Q8NEZ4     | 23     | 0.0005                 | 0.6036              |
| 29   | AR    | P10275     | 44     | 0.0028                 | 0.7444              | 64   | RICTOR| Q6R327     | 22     | 0.0006                 | 0.5982              |

(Continues)
Investigating the protein expression of HER2 and ATM together, we found that tumours with HER2 high/ATM low had the worst OS and DFS compared with HER2 high/ATM high, HER2 low/ATM low, or high. The expression of HER2/ATM was significantly associated with tumour grade, disease stage, tumour shape, lymph node and metastasis. Furthermore, multivariate analysis indicated that HER2-ATM expression is an independent predictor of OS and DFS. These findings were also confirmed using mRNA expression analysis, suggesting that co-expression of HER2 with ATM factors may be potential molecular biomarkers for predicting bladder cancer prognosis and disease aggressiveness. Our data was not in agreement with Stagni et al., who reported that ATM activation and HER2 positivity predicted the worst DFS in breast cancer patients and patients displaying ATM-p-negative and HER2-positive have moderate DFS suggesting that ATM sustained tumorigenicity of HER2 in breast cancer.

Understanding the molecular interactions between ATM and HER2 is particularly important in the prognosis and the treatment planning of bladder cancer patients. Reddy et al. demonstrated that phosphorylation of ATM on Ser1981 is dependent on the expression of HER2 in breast cancer mouse model. A positive feedback loop between ATM and HER2 was suggested where HER2 induces phosphorylation activation of ATM. The latter supports the binding between HER2 and HSP90, enhancing HER2 expression and tumour progression.

It has been suggested that ATM’s role as tumour suppressor gene altered to be tumour promoter in HER2-positive tumours. Yan et al.’s results indicated that silencing the activity of HER2 using specific inhibitor, shRNA or using ERBB2 mutated cells inhibit the activation of ATM and ATR signalling pathway in response to γ-irradiation leading to G2/M cell cycle arrest. Overall, the analysis of several cohorts of patients with various malignancies revealed a strong negative correlation between the expression of HER2 and ATM at both protein and mRNA levels. Interestingly, the inverse relationship between the two proteins HER2+/ATM- was significantly associated with poor DFS. This finding is particularly important and showed that HER2 and ATM may serve as a prognostic biomarker. Furthermore, DFS is regarded as a way to evaluate how well the treatment works and has also become a commonly used parameter to assess the efficacy of new cancer drugs. Published data demonstrated that targeting the ATM may impact treatment efficacy and improve the outcome of cancer patients. Altogether, this data indicates that targeting patients carrying both HER2 and ATM mutations using anti-ATM and anti-HER2 combination therapy may provide extra benefit for cancer patients.

We next sought to investigate the overlapping proteins between HER2 and ATM pathways to provide deeper insight into the molecular mechanisms of this relation. We identified three common pathways: Generic Transcription Pathway, RNA Polymerase II Transcription and Gene expression (Transcription), which were analysed further using PPI network and module analysis. Sixty-six overlapping proteins were identified with a direct link to both HER2 and ATM proteins, including AKT1, TP53, BRCA1, PTEN, CHEK2, ABL1, KRAS, MSH2, EGFR, CDK4, MAPK1, RAD51, mTOR, RB1, PARP1.

| Rank | Name | Uniprot ID | Degree | Betweenness centrality | Closeness centrality | Rank | Name | Uniprot ID | Degree | Betweenness centrality | Closeness centrality |
|------|------|-----------|--------|------------------------|---------------------|------|------|-----------|--------|------------------------|---------------------|
| 31   | VEGFA| Q9H1W9    | 42     | 0.0021                 | 0.7283              | 64   | RPTOR | Q8N122    | 22     | 0.0003                 | 0.5982              |
| 32   | MAPK1| P23982    | 41     | 0.0030                 | 0.7204              | 32   | RRM2  | P31350    | 18     | 0.0002                 | 0.5776              |
| 32   | ABL1 | P00519    | 41     | 0.0030                 | 0.7204              | 32   | RHEB  | P15382    | 17     | 0.0000                 | 0.5726              |
| 32   | FOXO1| Q9NZC7    | 41     | 0.0030                 | 0.7204              | 32   | WWOX  | Q9H1W9    | 41     | 0.0032                 | 0.7204              |

TABLE 4 (Continued)
and more. Also, PPI centrality measure of this sub-network indicates the importance of these intermediate proteins to the interaction between HER2 and ATM.

The pathway enrichment analysis revealed that the 66 overlapping proteins involved significantly in the regulation of apoptotic process, cell proliferation, cellular response to DNA damage stimulus, cell cycle arrest, response to a drug, regulation of gene expression, protein phosphorylation for the GO Biological process term annotation, and more. Interestingly, our finding showed significant alteration to AKT1, AKT2, TSC2, RPTOR and mTOR expression, which followed ATM status when HER2 was low. ABL1, SMAD4, RB1 and PARP1 showed significant alteration in the opposite direction to ATM status when HER2 was low. ABL1, SMAD4, RB1 and PARP1 showed significant alteration to AKT1, which deactivates STING signalling and suppresses antiviral and antitumor immunity. In contrast, ATM was demonstrated to be essential for activation of AKT in response to insulin or γ-radiation. As for TP53, the combined mutated status of TP53 and ATM was previously linked to clinical response to chemotherapy. Whereas TP53 mutants induce HER2 overexpression in cancer cells, which may constitute an anticancer resistance mechanism. To overcome cancer resistance to HER2 therapy, Fujimoto et al. suggested a combination treatment targeting PI3K/AKT/mTOR pathway in PIK3CA mutant HER2-positive breast cancer.

5 | CONCLUSION

To our knowledge, this is the first time where the inverse relationship between ATM and HER2 was highlighted in bladder cancer. The impact of such a relationship on the prognostic outcome of patients with bladder cancer was also described. Even though our data demonstrated potential overlapping proteins between ATM-HER2 pathways, which could contribute to bladder cancer pathogenesis, the exact molecular mechanism and biological significance of the crosstalk between HER2 and ATM still require further investigations to improve prognosis and treatment efficacy in bladder cancer. The main limitation of our study is that it was a retrospective observational study and further analyses with larger sample size are needed to investigate the relation between HER2, ATM and bladder cancer prognosis. Also, the results of the present study were based on bio-informatical analysis and must be validated further by experimental test.

FIGURE 4 GO functional enrichment and KEGG pathway analyses of the 66 overlapping proteins, HER2 and ATM. (A) The top significant enriched GO annotation Molecular Function, (B) Biological Process, (C) Cellular Component, (D) KEGG pathway analyses.
AUTHOR CONTRIBUTIONS
Nada Albarakati: Conceptualization (lead); data curation (lead); formal analysis (lead); methodology (lead); software (lead); writing – original draft (lead). Alaa Al-Shareeda: Investigation (supporting); writing – review and editing (equal). Majed Ramadan: Formal analysis (supporting); methodology (equal); writing – review and editing (equal). Batla Al-Sowayan: Investigation (supporting); writing – review and editing (equal). Ola Negm: Investigation (supporting); writing – review and editing (equal). Taoufik Nedjadi: Conceptualization (supporting); methodology (supporting); writing – review and editing (equal).

ACKNOWLEDGEMENTS
This work was supported by a grant from King Abdullah International Medical Research Center (Protocol No.: RJ17/072/J).

CONFLICT OF INTEREST
The authors declare no conflict of interest.

DATA AVAILABILITY STATEMENT
Data generated or analysed during this study are included in this published article and its supplementary information files. Also, both TCGA and GEO are publicly available as indicated in the materials and methods/study cohorts section.

ORCID
Nada Albarakati https://orcid.org/0000-0001-5135-8684

REFERENCES
1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7-33. doi:10.3322/caac.21654
2. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660
3. Sanli O, Dobruch J, Knowles MA, et al. Bladder cancer [Primer]. Nat Rev Dis Primers. 2017;3:17022. doi:10.1038/nrdp.2017.22
4. Glaser AP, Fantini D, Shilatifard A, Schaeffner EM, Meeks JJ. The evolving genomic landscape of urothelial carcinoma. Nat Rev Urol. 2017;14(4):215-229. doi:10.1038/nrurol.2017.11
5. Oh DY, Bang YJ. HER2-targeted therapies - a role beyond breast cancer. Nat Rev Clin Oncol. 2020;17(1):7-33. doi:10.1038/s41571-019-0268-3
6. De Keukeleire S, De Maeseneer D, Jacobs C, Rottey S. Targeting FGFR in bladder cancer: ready for clinical practice? Nat Rev Urol. 2015;12(4):197-210. doi:10.1038/nrurol.2015.30
7. Yu K, Shi J, Cai C, et al. The potential role of FGFR3 amplification in bladder cancer progression. J Cancer. 2019;10(17):4265-4273. doi:10.7150/jca.34119
8. Mahboubi M, Al-Shareeda A. FGFR3 in Bladder Cancer: A Comprehensive Review. Cancers (Basel). 2020;12(11). doi:10.3390/cancers12113282
9. Park JH, Kang SH, Shin JH, et al. FGFR3 amplification is associated with aggressive phenotypes in bladder cancer. J Korean Med Sci. 2020;35(18):e383. doi:10.3346/jkms.2020.35.e383
10. Lopez-Beltran A, Cimadomo A, Blanca A, et al. Immune check-point inhibitors for the treatment of bladder cancer. Cancer. 2021;13(1):131. doi:10.3390/cancers13010131
11. Kruger S, Weitsch G, Buttnert H, et al. HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications. Int J Cancer. 2002;102(5):514-518. doi:10.1002/ijc.7031
12. Hussain MH, MacVicar GR, Petrylak DP, et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol. 2007;25(16):2218-2224. doi:10.1200/jco.2006.08.0994
13. Li Z, Chen S, Feng W, et al. A pan-cancer analysis of HER2 index revealed transcriptional pattern for precise selection of HER2-targeted therapy. EBioMedicine. 2020;62:103074. doi:10.1016/j.ebiom.2020.103074
14. Agrawal V, Bhatti N, Pandey R. Human epidermal growth factor receptor 2 (HER2) gene amplification in non-muscle-invasive urothelial bladder cancers: Identification of patients for targeted therapy. Arab J Urol. 2020;18(4):267-272. doi:10.1080/209098x.2020.181483
15. Meric-Bernstam F, Johnson AM, Dumbraja EEI, et al. Advances in HER2-targeted therapy: novel agents and opportunities beyond breast and gastric cancer. Clin Cancer Res. 2019;25(7):2033-2041. doi:10.1158/1078-0432.ccr-18-2275
16. Tan TZ, Rouanne M, Tan KT, Huang RY, Thierry JP. Molecular subtypes of urothelial bladder cancer: results from a meta-cohort analysis of 2411 tumors. Eur Urol. 2019;75(3):423-432. doi:10.1016/j.eururo.2018.08.027
17. Zhu S, Yu W, Yang X, Wu C, Cheng F. Traditional classification and novel subtyping systems for bladder cancer. Front Oncol. 2020;10:102. doi:10.3389/fonc.2020.00102
18. Gan K, Gao Y, Liu K, Xu B, Qin W. The clinical significance and prognostic value of HER2 expression in bladder cancer: a meta-analysis and a bioinformatic analysis. Front Oncol. 2021;11:653491. doi:10.3389/fonc.2021.653491
19. Majumder A, Sandhu M, Banerji D, Steri V, Olshen A, Moasser MM. The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers. Sci Rep. 2021;11(1):9091. doi:10.1038/s41598-021-88683-w
20. Patelli G, Zeppellini A, Spina F, et al. The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives. Cancer Treat Rev. 2022;104:102351. doi:10.1016/j.ctrv.2022.102351
21. Wang X, Hu W, Xie L. Response to anti-HER2-based treatment in a patient with bladder adenocarcinoma harboring HER2 amplification and S310F mutation discovered by next-generation sequencing: a case report. Onco Targets Ther. 2020;13:4249-4255. doi:10.2147/ott.s247515
22. Oudard S, Culine S, Vano Y, et al. Multicentre randomised phase II trial of gemicabine-platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2. Eur J Cancer. 2015;51(1):45-54. doi:10.1016/j.ejca.2014.10.009
23. Jiang Q, Xie MX, Zhang XC. Complete response to trastuzumab and chemotherapy in recurrent urothelial bladder carcinoma with HER2 gene amplification: A case report. World J Clin Cases. 2020;8(3):594-599. doi:10.12998/wjcc.v8.i3.594
24. Grivas PDDM, Hussain M. Urothelial carcinomas: a focus on human epidermal receptors signaling. Am J Transl Res. 2011;15(4):362-373.
25. Shiloh Y, Ziv Y. The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nat Rev Mol Cell Biol. 2020;21(4):197-210. doi:10.1038/s41598-019-0268-3
26. Yin M, Grivas P, Emaneckho H, et al. ATM/RB1 mutations predict shorter overall survival in urothelial cancer. Oncotarget. 2018;9(24):16891-16898. doi:10.18632/oncotarget.24738
27. Plimack ER, Dunbrack RL, Brennan TA, et al. Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. Eur Urol. 2015;68(6):959-967. doi:10.1016/j.eururo.2015.07.009
28. Stagni V, Manni I, Oropallo V, et al. ATM kinase sustains HER2 tumorigenicity in breast cancer. Nat Commun. 2015;6:6886. doi:10.1038/ncomms7886

29. Stagni V, Oropallo V, Barilla D. ATM: An unexpected tumor-promoting factor in HER2-expressing tumors. Mol Cell Oncol. 2016;3(2):e1054511. doi:10.2173256150.2015.1054511

30. Angell HK, Lee J, Kim KM, et al. PD-L1 and immune infiltrates are differentially expressed in distinct subgroups of gastric cancer. Onco Targets Ther. 2019;8(2):e1544442. doi:10.21624/02x.2018.1544442

31. Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. UALCAN: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401-404. doi:10.1158/2159-8290.cd-12-0095

32. Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1. doi:10.1126/scisignal.2004088

33. Robertson AG, Kim J, Al-Ahmadi H, et al. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell. 2017;171(3):540-556.e25. doi:10.1016/j.cell.2017.09.007

34. Kim WJ, Kim EJ, Kim SK, et al. Predictive value of progression-associated gene expression and survival analyses. Neoplasia. 2017;19(8):649-658. doi:10.1016/j.neo.2017.05.002

35. Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401-404. doi:10.1158/2159-8290.cd-12-0095

36. Lee JS, Leem SH, Lee SY, et al. Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors. J Clin Oncol. 2010;28(16):2660-2667. doi:10.1200/jco.2009.25.0977

37. Lindgren D, Sjödahl G, Lauss M, et al. Integrated genomic and molecular characterization of muscle-invasive bladder carcinoma. PLoS One. 2012;7(6):e38863. doi:10.1371/journal.pone.0038863

38. Croft D, O’Kelly G, Wu G, et al. Reactome: a database of reactions, pathways and biological processes. Nucleic Acids Res. 2011;39(Database issue):D691-D697. doi:10.1093/nar/gkq1018

39. von Mering C, Huynen M, Jaeggi D, Schmidt S, Bork P, Snel B. STRING: a database of predicted functional associations between proteins. Nucleic Acids Res. 2003;31(1):258-61. doi:10.1093/nar/gkq034

40. Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498-2504. doi:10.1101/gr.1239303

41. Assenov Y, Ramirez F, Schelhorn SE, Lengauer T, Albrecht M. Computing topological parameters of biological networks. Bioinformatics. 2008;24(2):282-284. doi:10.1093/bioinformatics/btm554

42. Chin CH, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY. cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 2014;8:511. doi:10.1186/1755-0805-8-s4-s11

43. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44-57. doi:10.1038/nprot.2008.211

44. Voutsadakis IA. Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis than Targatable Molecular Defects beyond Immunotherapies. Curr Oncol. 2022;29(3):1390-1407. doi:10.3390/curreono29030117

45. Wen L, Britton CJ, Garje R, Darbro BW, Pacikam VT. The emerging role of somatic tumor sequencing in the treatment of urothelial cancer. Asian J Urol. 2021;8(4):391-399. doi:10.1016/j.ajur.2021.06.005

46. Zangouei AS, Barjasteh AH, Rahimi HR, Mojarrad M, Moghbeli M. Role of tyrosine kinases in bladder cancer progression: an overview. Cell Commun Signal. 2020;18(1):127. doi:10.1186/s12964-020-00625-7

47. Yi R, Lin A, Cao M, Xu A, Luo P, Zhang J. ATM mutations benefit bladder cancer patients treated with immune checkpoint inhibitors by acting on the tumor immune microenvironment. Front Genet. 2020;11:933. doi:10.3389/fgene.2020.00933

48. Knowles MA, Hurst CD. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversify. Nat Rev Cancer. 2015;15(1):25-41. doi:10.1038/nrc3817

49. El Ochi MR, Ouakil M, Bouaiti E, et al. Expression of human epidermal growth factor receptor 2 in bladder urothelial carcinoma. BMC Clin Pathol. 2017;17:3. doi:10.1186/s12907-017-0046-z

50. Yin M, Grivas P, Mortazavi A, et al. ATM mutation is associated with shorter overall survival in relapsed/advanced urothelial cancer. J Clin Oncol. 2019;37(7_suppl):370. doi:10.1200/JCO.2019.37.7_suppl.370

51. Reddy JP, Peddibhotla S, Bu W, et al. Defining the ATM-mediated barrier to tumorigenesis in somatic mammary cells following ErbB2 activation. Proc Natl Acad Sci U S A. 2010;107(8):3728-3733. doi:10.1073/pnas.0910665107

52. Yan Y, He AL, Greer PM, et al. A novel function of HER2/Neu in the activation of G2/M checkpoint in response to γ-irradiation. Oncogene. 2015;34(17):2215-2226. doi:10.1038/onc.2014.167

53. Wu S, Zhang Q, Zhang F, et al. HER2 recruits AKT1 to disrupt STING signalling and suppress antiviral defence and antitumour immunity. Nat Cell Biol. 2019;21(8):1027-1040. doi:10.1038/s41556-019-0352-z

54. Viniegra JG, Martinez N, Madrassari P, et al. Full activation of PKB/Akt in response to insulin or ionizing radiation is mediated through ATM. J Biol Chem. 2005;280(6):4029-4036. doi:10.1074/jbc.M410344200

55. Jiang H, Reinhardt HC, Bartkova J, et al. The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev. 2009;23(16):1895-1909. doi:10.1101/gad1815309

56. Román-Rosales AA, García-Villa E, Herrera LA, Gariglio P, Díaz-Chávez J. Mutant p53 gain of function induces HER2 over-expression in cancer cells. BMC Cancer. 2018;18(1):709. doi:10.1186/s12885-018-4613-1

57. Vernieri C, Milano M, Brambilla M, et al. Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives. Crit Rev Oncol Hematol. 2019;139:53-66. doi:10.1016/j.critrevonc.2019.05.001

58. Fujimoto Y, Morita TY, Ohashi A, et al. Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells. Sci Rep. 2020;10(1):21762. doi:10.1038/s41598-020-78646-y

SUPPORTING INFORMATION
Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Albarakati N, Al-Shareeda A, Ramadan M, Al-Sowayan B, Negm O, Nedjadi T. Interaction between HER2 and ATM predicts poor survival in bladder cancer patients. J Cell Mol Med. 2022;26:4959-4973. doi: 10.1111/jcmm.17512